Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 29, Issue 4, 2016, Pages 537-543

  Kienast, Carolin ^a   Moya, Walter ^b   Rodriguez, Oswaldo ^c   Jijón, Alfredo ^d   Geipel, Annegret ^e  

^a Department of Obstetrics and Gynecology   (Germany)

^b UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

^c Roche Diagnostics Ecuador   (Ecuador)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Angiogenic factors; Ecuador; fetal growth restriction; high altitude; placental growth factor; pre eclampsia; soluble fms like tyrosine kinase 1; uterine artery Doppler

Indexed keywords

PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOPPLER FLOWMETRY; ECUADOR; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; UTERINE ARTERY DOPPLER; BLOOD; CASE CONTROL STUDY; DOPPLER ULTRASONOGRAPHY; ECHOGRAPHY; FETAL GROWTH RETARDATION; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREGNANCY; SENSITIVITY AND SPECIFICITY; UTERINE ARTERY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; ECUADOR; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; RISK FACTORS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, DOPPLER; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84950327141     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2015.1012063     Document Type: Article

References (38)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet 2010;376:631-44.
2. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-83.
3. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005;46:1077-85.
4. Kinzler WL, Vintzileos AM. Fetal growth restriction: A modern approach. Curr Opin Obstet Gynecol 2008;20:125-31.
5. Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010;151:122-9.
6. De Vivo A, Baviera G, Giordano D, et al. Endoglin, PLGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008;87:837-42.
7. Hertig A, Berkane N, Lefevre G. Maternal serum sFlt-1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004;50:1702-3.
8. McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004;191:1240-6.
9. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-82.
10. Tjoa ML, van Vugt JM, Mulders MA, et al. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001;98: 600-7.
11. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PLGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202: 161e1-11.
12. Gómez O, Martínez JM, Figueras F, et al. Uterine artery Doppler at 11-14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol 2005;26:490-4.
13. Albaiges G, Missfelder-Lobos H, Lees C, et al. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000;96: 559-64.
14. Bower S, Bewley S, Campbell S. Improved prediction of preeclampsia by two stage screening of uterine arteries using the early diastolic notch and color Doppler imaging. Obstet Gynecol 1993;82:78-83.
15. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. JAHA 2007;49:818-24.
16. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2008;102:146-51.
17. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
18. Escudero C, Calle A. Hierro, oxígeno y desarrollo placentario en la génesis de la preeclampsia. Efectos de la altura en Ecuador. Rev Méd Chile 2006;134:491-8.
19. Keyes LE, Armaza JF, Niermeyer S, et al. Intrauterine growth restriction, preeclampsia and intrauterine mortality at high altitude in Bolivia. Pediatr Res 2003;54:20-5.
20. Mikolajczyk RT, Zhang J, Betran AP, et al. A global reference for fetal-weight and birthweight percentiles. Lancet 2011;377: 1855-61.
21. Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, et al. Uterine artery Doppler and sFlt-1/PLGF ratio: usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet Gynecol 2013;41:530-7.
22. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326.e1-13.
23. Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: A systematic review. Obstet Gynecol 2007;109:168-80.
24. Crispi F, Domínguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006;195: 201-7.
25. Myers JE, Kenny LC, McCowan LM, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: A predictive test accuracy study. BJOG 2013; 120:1215-23.
26. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endogen and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
27. Diguisto C, Le Gouge A, Piver E, et al. Second-trimester uterine artery Doppler, PLGF, sFlt-1, sEndoglin, and lipid-related markers for predicting preeclampsia in a high-risk population. Prenat Diagn 2013;33:1070-4.
28. Verlohren S, Herraiz I, Lapaire O, et al. New gestational phasespecific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346-52.
29. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010;5:173-92.
30. Dávila RD, Julian CG, Wilson MJ, et al. Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitude afforded by Andean ancestry? Reprod Sci 2010;17: 861-70.
31. Julian CG, Galan HL, Wilson MJ, et al. Lower uterine artery blood flow and higher endothelin relative to nitric oxide metabolite levels are associated with reductions in birth weight at high altitude. Am J Physiol Regul Integr Comp Physiol 2008;295:R906-15.
32. Zamudio S, Borges M, Echalar L, et al. Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy. Biol Reprod 2014;90:42.
33. Krampl E, Lees C, Bland JM, et al. Fetal Doppler velocimetry at high altitude. Ultrasound Obstet Gynecol 2001;18:329-34.
34. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: A systematic review and meta-analysis. BJOG 2012;119:778-87.
35. Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
36. Karagiannis G, Akolekar R, Sarquis R, et al. Prediction of smallfor-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 2011;29:148-54.
37. Poon L, Syngelaki A, Akolekar R, et al. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther 2013;33:16-27.
38. Parra-Cordero M, Rodrigo R, Barja P, et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol 2013;41: 538-44.